Advice
following a full submission:
dapagliflozin (Forxiga®) is accepted for use within NHSScotland.
Indication under review: in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.
In a randomised, double-blind, phase III study, dapagliflozin demonstrated a significant reduction in the composite outcome of hospitalisation for heart failure, urgent heart failure visit and cardiovascular death compared with placebo in patients with heart failure with reduced ejection fraction receiving current standard of care.
Medicine details
- Medicine name:
- dapagliflozin (Forxiga)
- SMC ID:
- SMC2322
- Indication:
In adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 12 April 2021